Frank Torti
CIK 1647805 · President and Vant Chair · last filed 2026-07-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$550.56M
Companies
8
Total Filings
33
Lifetime Open-Market Net
-$81.92M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ROIV | President and Vant Chair | 13,536,202 | $37.37 | $505.85M | -$82.04M | 5 | 2026-07-02 |
| IMVT | Director | 1,009,228 | $44.30 | $44.71M | $116.2K | 8 | 2026-04-09 |
| ABUS | Director | — | $4.84 | — | $0 | 7 | 2024-05-24 |
| Sio Gene Therapies Inc. (SIOX) Delisted | Director | — | $0.48 | — | $0 | 1 | 2021-04-19 |
| Immunovant, Inc. (IMVTW) Delisted | Director | 28,400 | — | — | $0 | 2 | 2020-05-18 |
| Sio Gene Therapies Inc. (AXGT) Delisted | Director | — | — | — | $0 | 1 | 2020-04-17 |
| Myovant Sciences Ltd. (MYOV) Delisted | Director | — | $26.98 | — | $0 | 2 | 2019-08-27 |
| Urovant Sciences Ltd. (UROV) Delisted | Director | — | $16.24 | — | $0 | 2 | 2019-07-11 |
Recent Filings · Page 2 of 4
33 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-05-24 | ABUS | Grant (A) | — | $0 | EDGAR |
| 2024-04-04 | IMVT | Grant (A) | +120,400 | $0 | EDGAR |
| 2023-05-26 | ABUS | Grant (A) | — | $0 | EDGAR |
| 2023-04-14 | IMVT | Grant (A) | +121,916 | $0 | EDGAR |
| 2022-09-29 | IMVT | Buy (P) | +20,000 | $116.2K | EDGAR |
| 2022-08-19 | IMVT | Grant (A) | +225,632 | $0 | EDGAR |
| 2022-05-26 | ABUS | Grant (A) | — | $0 | EDGAR |
| 2022-01-12 | IMVT | Grant (A) | +100,126 | $0 | EDGAR |
| 2021-06-07 | ABUS | Grant (A) | — | $0 | EDGAR |
| 2021-04-19 | Sio Gene Therapies Inc. (SIOX) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.